UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

38.03 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2026 Add to My Watchlist

Price and Volume

Volume	1,111
Open	38.03
Bid (Size)	38.10 (100)
Ask (Size)	38.40 (100)
Prev. Close	38.03
Today's Range	38.03 - 38.03
52wk Range	13.26 - 39.59
Shares Outstanding	36,130,121
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

July 08, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗

June 30, 2026

Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.

Via The Motley Fool

Performance

YTD	+67.5%	+67.5%
1 Month	+39.6%	+39.6%
3 Month	+99.1%	+99.1%
6 Month	+64.3%	+64.3%
1 Year	+177.4%	+177.4%

More News

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗

June 14, 2026

Via The Motley Fool

UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth ↗

June 08, 2026

Via Chartmill

UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates ↗

May 06, 2026

Via Chartmill

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

June 02, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 01, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

Via The Motley Fool

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

Via The Motley Fool

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

May 15, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

May 13, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen (URGN) Q1 2026 Earnings Transcript ↗

May 07, 2026

Via The Motley Fool

UroGen Pharma to Present at Upcoming Investor Conferences

May 07, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

May 06, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

April 29, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

March 30, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗

March 23, 2026

Via The Motley Fool

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗

March 18, 2026

Via The Motley Fool

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗

March 18, 2026

Via The Motley Fool

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗

March 18, 2026

Via The Motley Fool

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗

March 18, 2026

Via The Motley Fool

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

March 13, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen (URGN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Via The Motley Fool

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?

Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.

What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?

UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?

The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market

What is the current price of UroGen Pharma Ltd. - Ordinary Shares?

The current price of UroGen Pharma Ltd. - Ordinary Shares is 38.03

When was UroGen Pharma Ltd. - Ordinary Shares last traded?

The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 07/08/26 04:00 PM ET

What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?

The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 1.37B

How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?

UroGen Pharma Ltd. - Ordinary Shares has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.